US FDA explains how to assess treatment-emergent suicidal ideation, behaviour in drug trials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued for consultation an updated draft guidance on how companies can prospectively assess treatment-emergent suicidal ideation and behaviour in clinical trials of drugs and biologics1,2.